Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
Status:
Completed
Trial end date:
2020-01-30
Target enrollment:
Participant gender:
Summary
This study will evaluate higher versus standard adalimumab dosing regimens for induction and
maintenance therapy in subjects with moderately to severely active Crohn's Disease and
evidence of mucosal ulceration.